Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUST: Bintrafusp Alfa and Doxorubicin in Advanced Sarcoma
NCT04874311Phase 2Active, not recruiting
- Sponsor
- Institut Bergonié
- Start
- Mar 2022
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in soft tissue sarcoma (STS), sponsored by Institut Bergonié. Started Mar 2022; status: active, not recruiting.
02
Drugs
bintrafusp alfa
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04874311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874311.